克拉生坦治疗动脉瘤性蛛网膜下腔出血:更新的Meta分析及试验序贯分析
该Meta分析纳入5项研究共2317例动脉瘤性蛛网膜下腔出血患者,评估克拉生坦对内皮素受体拮抗的效果。结果显示克拉生坦显著降低需挽救治疗的延迟缺血性神经功能缺损和血管痉挛风险,但未显著影响死亡率、血管痉挛相关病残、新发脑梗死或3个月不良临床结局。试验序贯分析提示研究对死亡率和血管痉挛相关病残的评估把握度不足。
要点
- 克拉生坦显著降低需挽救治疗的延迟缺血性神经功能缺损风险(RR 0.625,95%CI 0.462-0.846)。
- 克拉生坦显著降低中重度血管造影血管痉挛风险(RR 0.543,95%CI 0.464-0.635)。
- 10-15 mg/h克拉生坦较5 mg/h与更低的血管痉挛和新发脑梗死发生率相关。
核心结论
- 克拉生坦降低需挽救治疗的延迟缺血性神经功能缺损和中重度血管痉挛风险。
- 需基于个体患者数据、不同克拉生坦剂量和更精细结局指标的进一步Meta分析来明确克拉生坦改善蛛网膜下腔出血后结局的疗效。
研究设计与样本
- 系统检索PubMed、Embase和Cochrane数据库筛选合格研究。
- 纳入5项研究,共2317例患者。
- 主要结局为6周时需挽救治疗的延迟缺血性神经功能缺损、全因死亡率和血管痉挛相关病残;次要结局为中重度血管造影血管痉挛、新发脑梗死和3个月不良临床结局。
- 进行试验序贯分析评估所需信息量和相对风险降低的α消耗监测边界效应。
- 按克拉生坦剂量进行分层分析。
主要发现
- 克拉生坦显著降低需挽救治疗的延迟缺血性神经功能缺损风险(RR 0.625;95%CI 0.462-0.846)。
- 克拉生坦显著降低血管痉挛风险(RR 0.543;95%CI 0.464-0.635)。
- 克拉生坦未显著影响死亡率或血管痉挛相关病残(RR 0.775;95%CI 0.578-1.039)。
- 克拉生坦未显著影响新发脑梗死(RR 0.604;95%CI 0.383-0.952)。
- 克拉生坦未显著影响临床结局(RR 1.131;95%CI 0.959-1.334)。
关键数值与推荐
- 需挽救治疗的延迟缺血性神经功能缺损:RR 0.625(95%CI 0.462-0.846)。
- 血管痉挛:RR 0.543(95%CI 0.464-0.635)。
- 死亡率或血管痉挛相关病残:RR 0.775(95%CI 0.578-1.039)。
- 新发脑梗死:RR 0.604(95%CI 0.383-0.952)。
- 临床结局:RR 1.131(95%CI 0.959-1.334)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 试验序贯分析揭示研究对克拉生坦在死亡率和血管痉挛相关病残方面的效应评估把握度不足。
- 需基于个体患者数据、不同克拉生坦剂量和更精细结局指标的进一步Meta分析来明确克拉生坦改善蛛网膜下腔出血后结局的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clazosentan, an endothelin receptor antagonist, reduced vasospasm and delayed ischemic neurologic deficit (DIND) but did not improve outcome after subarachnoid hemorrhage (SAH) in clinical trials. However, a lack of dose-dependent analysis and potential overestimation of clazosentan's effect are concerning. We used stratified analysis and trial sequential analysis (TSA) of existing data to investigate the effects of clazosentan on SAH outcome. METHODS: Studies from PubMed, Embase, and Cochrane were reviewed for eligibility. Primary outcomes were DIND requiring rescue therapy, all-cause mortality, and vasospasm-related morbidity at 6 weeks. Secondary outcomes were moderate-to-severe angiographic vasospasm, new cerebral infarction, and poor clinical outcome at 3 months. TSA was performed to assess the required information size and the α-spending monitoring boundary effect of relative risk (RR) reduction. A stratified analysis of clazosentan dosage was performed. RESULTS: Five studies (N = 2317) were included. Clazosentan significantly reduced the risk of DIND requiring rescue therapy (RR, 0.625; 95% confidence interval [CI], 0.462-0.846) and vasospasm (RR, 0.543; 95% CI, 0.464-0.635), but did not significantly affect mortality or vasospasm-related morbidity (RR, 0.775; 95% CI, 0.578-1.039), new cerebral infarction (RR, 0.604; 95% CI, 0.383-0.952), or outcome (RR, 1.131; 95% CI, 0.959-1.334). TSA revealed that the studies were underpowered to evaluate the effects of clazosentan on mortality and vasospasm-associated morbidity. We found 10-15 mg/h of clazosentan administration was associated with lower rates of vasospasm and new cerebral infarctions compared with 5 mg/h. CONCLUSIONS: Clazosentan reduced the risk of DIND requiring rescue therapy and moderate-to-severe vasospasm. Further meta-analyses based on individual patient data with different clazosentan doses and more refined outcome measures are necessary to clarify clazosentan's efficacy in improving post-SAH outcome.
引用
- Cho SS, Kim SE, Kim HC, et al. Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis with Trial Sequential Analysis. World Neurosurg. 2018. PMID: 30508597. doi:10.1016/j.wneu.2018.10.213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。